Chondroitin Sulfate as a Lysosomal Enhancer Attenuates Lipid-Driven Inflammation via Lipophagy and Mitophagy
Marine Drugs · 2025
DOI: 10.3390/md23060228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Ting Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. Hauptthemen laut MEDLINE: Lysosomes, Mitophagy, Chondroitin Sulfates, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Natural Science Foundation of Shandong Province, Key Research and Development Program of of Shandong Province.
Abstract (Originalsprache)
Non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by lipid accumulation and chronic inflammation, lacks effective therapies targeting its multifactorial pathogenesis. This study investigates marine-derived chondroitin sulfate (CS) as a multi-organelle modulator capable of regulating lipid metabolism, oxidative stress, and inflammation in NASH. By employing subcellular imaging and organelle-specific labeling techniques, we demonstrate that CS restores lysosomal acidification in a NASH model, enabling the reduction of lipid droplets via lysosomal–lipid droplet fusion. Concurrently, CS upregulates dynamin-related protein 1 (DRP1), driving mitochondrial terminal fission to spatially isolate reactive oxygen species (ROS) segments for mitophagy, thereby reducing ROS levels. Notably, pharmacological inhibition of lysosomal activity using chloroquine or bafilomycin A1 abolished the therapeutic effects of CS, confirming lysosomal acidification as an essential prerequisite. Collectively, these findings reveal the potential of CS as a therapeutic agent for NASH and provide critical insights into the subcellular mechanisms underlying its protective effects, thus offering a foundation for future research and therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
- Engineering Research Center for Sugar and Sugar Complex, National-Local Joint Engineering Laboratory of Polysaccharide Drugs, Key Laboratory of Carbohydrate and Glycoconjugate Drug, Shandong Academy of Pharmaceutical Sc…
- Zhengzhou Advanced Research Institute for New Materials, Peking University, Zhengzhou 450046, China.
- National Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University, Qingdao 266237, China.
Förderung
- National Key R&D Program of China
- Natural Science Foundation of Shandong Province
- Key Research and Development Program of of Shandong Province
- Jinan Innovation Team Project of Colleges and Universities
- National Key R&D Program of China
- Key Research and Development Program of Shandong Province
Zitieren
APA
Sun, T., Lv, H., Shao, H., Zhang, X., Wang, A., Zhang, W., Liu, F., & Ling, P. (2025). Chondroitin Sulfate as a Lysosomal Enhancer Attenuates Lipid-Driven Inflammation via Lipophagy and Mitophagy. Marine Drugs. https://doi.org/10.3390/md23060228
Vancouver
Sun T, Lv H, Shao H, Zhang X, Wang A, Zhang W, et al. Chondroitin Sulfate as a Lysosomal Enhancer Attenuates Lipid-Driven Inflammation via Lipophagy and Mitophagy. Marine Drugs. 2025. doi:10.3390/md23060228
BibTeX
@article{Sun2025,
author = {Sun, Ting and Lv, Huimin and Shao, Huarong and Zhang, Xiuhua and Wang, Anqi and Zhang, Wei and Liu, Fei and Ling, Peixue},
title = {Chondroitin Sulfate as a Lysosomal Enhancer Attenuates Lipid-Driven Inflammation via Lipophagy and Mitophagy},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23060228}
}
EUVIMED